A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Clinical trial NCT07393282 · RECRUITING
Trial details
- NCT number
- NCT07393282
- Sponsor
- Regeneron Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-21
- Primary completion
- 2033-07-27
- Enrollment
- 270
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.